Nuvectis Pharma (NVCT) vs Wave Life Sciences (WVE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed Wave Life Sciences (WVE) over the past year, gaining 232.1% versus a loss of 50.8%. Wave Life Sciences is the larger company by market cap ($697.6 million vs $662.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVCT | WVE |
|---|---|---|
| Share price | $20.29 | $3.54 |
| Market cap | $662.35M | $697.55M |
| 1-day change | +1.30% | +0.57% |
| YTD return | +168.74% | -79.18% |
| 1-year return | +232.08% | -50.76% |
| 5-year return | — | -31.26% |
| EPS (TTM) | $-1.31 | $-1.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.28 | $21.73 |
| 52-week low | $5.55 | $3.43 |
| Distance from 52-week high | -30.69% | -83.71% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +74.47% | +410.17% |
| Average volume | 219.45K | 3.10M |
| Shares outstanding | 32.64M | 197.05M |
| Employees | 16 | 317 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed WVE by 282.8 percentage points over the past year.
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Healthcare · Biotechnology · 16 employees
About Wave Life Sciences
WVE stock →Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Healthcare · Biotechnology · 317 employees
NVCT vs WVE FAQ
Which is bigger, Nuvectis Pharma or Wave Life Sciences?
Wave Life Sciences (WVE) is larger, with a market capitalization of $697.55M compared with $662.35M for Nuvectis Pharma (NVCT).
Which stock has performed better over the past year, NVCT or WVE?
NVCT returned +232.08% over the past 12 months, compared with -50.76% for WVE (price return, excluding dividends). Past performance does not predict future results.
Are Nuvectis Pharma and Wave Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.